Lurker > DepreceV2

It looks like the redid the engine's shaders, but it still seems to have that pervasive "tint" that Fallout had. Won't be preordering or buying at launch because it is a Bethesda game. They've all been crap at launch.

it has like 1000s planet = procedural generation = shit

yeah tht's bullshit
even with a pass it would still block you if you go more thn 30 seconds per post

good try vice!

The bot, which Kilcher called GPT-4chan, the most horrible model on the interneta reference to GPT-3, a language model developed by Open AI that uses deep learning to produce textwas shockingly effective and replicated the tone and feel of 4chan posts. The model was good in a terrible sense, Klicher said in a video about the project. It perfectly encapsulated the mix of offensiveness, nihilism, trolling, and deep distrust of any information whatsoever that permeates most posts on /pol.



It could generate extremely toxic content at a massive, sustained scale, Michel said. Obviously theres already a ton of human trolls on the internet that do that the old fashioned way. Whats different here is the sheer amount of content it can create with this system, one single person was able to post 30,000 comments on 4chan in the space of a few days. Now imagine what kind of harm a team of ten, twenty, or a hundred coordinated people using this system could do.



Kathryn Cramer, a Complex Systems & Data Science graduate student at the University of Vermont, pointed out that GPT-3 has guardrails that prevent it from being used to build this kind of racist bot and that Kilcher had to use GPT-J to build his system. I tried out the demo mode of your tool 4 times, using benign tweets from my feed as the seed text, Cramer said in a thread on Hugging Face. In the first trial, one of the responding posts was a single word, the N word. The seed for my third trial was, I think, a single sentence about climate change. Your tool responded by expanding it into a conspiracy theory about the Rothschilds and Jews being behind it.

Oh yeah I would echo starting with one of the GBA games, they're easy to get into and straight forward. I would suggest Sacred Stones, it doesn't have the stand out bad maps that FE7 has or the awkward "no item use in prep menu" thing Binding Blade has. Also lets you start on its hard mode from the first playthrough, which is not going to be hard for anyone who has played a Fire Emblem before but is more engaging than FE7 normal mode which is a joke.

Opinions range from "utter garbage, the worst blight on humanity" to "lots of different games to appeal to lots of people"

The real Chad was Claude the whole time.

https://twitter.com/PatrickBlinders/status/1535458650206117888

Forms don't even matter anymore

She literally posted a tweet saying this was a lie. And shes rich herself

So where's the MW2 remake

how long before big pharma buys the company and buries it

this topic needs to be kept bumped for at LEAST to 500 and everyone who posts should bookmark this article to check in to the company periodically for updates. i've bookmarked it. so should you.

It was a small trial, just 18 rectal cancer patients, every one of whom took the same drug.

But the results were astonishing. The cancer vanished in every single patient, undetectable by physical exam; endoscopy; positron emission tomography, or PET scans; or MRI scans.

Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, an author of a paper published Sunday in the New England Journal of Medicine describing the results, which were sponsored by drug company GlaxoSmithKline, said he knew of no other study in which a treatment completely obliterated a cancer in every patient.

I believe this is the first time this has happened in the history of cancer, Diaz said.

Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, who was not involved with the study, said he also thought this was a first.
A complete remission in every single patient is unheard-of, he said.

These rectal cancer patients had faced grueling treatments chemotherapy, radiation and, most likely, life-altering surgery that could result in bowel, urinary and sexual dysfunction. Some would need colostomy bags.

They entered the study thinking that, when it was over, they would have to undergo those procedures because no one really expected their tumors to disappear.

But they got a surprise: No further treatment was necessary.

There were a lot of happy tears, said Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and a co-author of the paper, which was presented Sunday at the annual meeting of the American Society of Clinical Oncology.
Another surprise, Venook added, was that none of the patients had clinically significant complications.

On average, 1 in 5 patients have some sort of adverse reaction to drugs like the one the patients took, dostarlimab, known as checkpoint inhibitors. The medication was given every three weeks for six months and cost about $11,000 per dose. It unmasks cancer cells, allowing the immune system to identify and destroy them.

While most adverse reactions are easily managed, as many as 3% to 5% of patients who take checkpoint inhibitors have more severe complications that, in some cases, result in muscle weakness and difficulty swallowing and chewing.

The absence of significant side effects, Venook said, means that either they did not treat enough patients or, somehow, these cancers are just plain different.

In an editorial accompanying the paper, Dr. Hanna K. Sanoff of the University of North Carolinas Lineberger Comprehensive Cancer Center, who was not involved in the study, called it small but compelling. She added, though, that it is not clear if the patients are cured.

Very little is known about the duration of time needed to find out whether a clinical complete response to dostarlimab equates to cure, Sanoff said in the editorial.
Dr. Kimmie Ng, a colorectal cancer expert at Harvard Medical School, said that while the results were remarkable and unprecedented, they would need to be replicated.

The inspiration for the rectal cancer study came from a clinical trial Diaz led in 2017 that Merck, the drugmaker, funded. It involved 86 people with metastatic cancer that originated in various parts of their bodies. But the cancers all shared a gene mutation that prevented cells from repairing damage to DNA. These mutations occur in 4% of all cancer patients.

Patients in that trial took a Merck checkpoint inhibitor, pembrolizumab, for up to two years. Tumors shrank or stabilized in about one-third to one-half of the patients, and they lived longer. Tumors vanished in 10% of the trials participants.

That led Cercek and Diaz to ask: What would happen if the drug were used much earlier in the course of disease, before the cancer had a chance to spread?

They settled on a study of patients with locally advanced rectal cancer tumors that had spread in the rectum and sometimes to the lymph nodes but not to other organs. Cercek had noticed that chemotherapy was not helping a portion of patients who had the same mutations that affected the patients in the 2017 trial. Instead of shrinking during treatment, their rectal tumors grew.

Perhaps, Cercek and Diaz reasoned, immunotherapy with a checkpoint inhibitor would allow such patients to avoid chemotherapy, radiation and surgery.
Diaz began asking companies that made checkpoint inhibitors if they would sponsor a small trial. They turned him down, saying the trial was too risky. He and Cercek wanted to give the drug to patients who could be cured with standard treatments. What the researchers were proposing might end up allowing the cancers to grow beyond the point at which they could be cured.
It is very hard to alter the standard of care, Diaz said. The whole standard-of-care machinery wants to do the surgery.

Finally, a small biotechnology firm, Tesaro, agreed to sponsor the study. Tesaro was bought by GlaxoSmithKline, and Diaz said he had to remind the larger company that they were doing the study company executives had all but forgotten about the small trial.
Their first patient was Sascha Roth, then 38. She first noticed some rectal bleeding in 2019 but otherwise felt fine she is a runner and helps manage a family furniture store in Bethesda, Maryland.

During a sigmoidoscopy, she recalled, her gastroenterologist said, Oh no. I was not expecting this!

The next day, the doctor called Roth. He had had the tumor biopsied. Its definitely cancer, he told her.

I completely melted down, she said.

Soon, she was scheduled to start chemotherapy at Georgetown University, but a friend had insisted she first see Dr. Philip Paty at Memorial Sloan Kettering. Paty told her he was almost certain her cancer included the mutation that made it unlikely to respond well to chemotherapy. It turned out, though, that Roth was eligible to enter the clinical trial. If she had started chemotherapy, she would not have been.
Not expecting a complete response to dostarlimab, Roth had planned to move to New York for radiation, chemotherapy and possibly surgery after the trial ended. To preserve her fertility after the expected radiation treatment, she had her ovaries removed and put back under her ribs.
After the trial, Cercek gave her the news.
We looked at your scans, she said. There is absolutely no cancer. She did not need any further treatment.

I told my family, Roth said. They didnt believe me.

But two years later, she still does not have a trace of cancer.

Suicide attempts involving substances rose across the board in 9- to 18-year-olds, but the data suggests the youth mental health crisis is worsening, and skewing into increasingly younger age groups. Its rare for children and teenagers to die by overdose: Of the more than 1.2 million ingestion cases Marshall and her colleagues studied over 20 years, 1,005 resulted in death. But almost 29% of cases had a moderate or major health effect on the child or teenager.

it's real

i'm pretty sure it's been back on for months, but only for a small number of articles.

Yeah, nothing brings out the racist boomers quite like the Yahoo comment section.

Did this just happen today or yesterday? It was still closed on Sunday

Update: I didn't go to work today instead i called in, spoke with some people about what was going on, went to an urgent clinic they recommended, got an x-ray, turns out thankfully no broken bones but I have n infection called Cellulitis and now I'm currently in line to get the prescription pain killers and the antibodotics for it. Oh and I'm due to report back to work tomorrow and a follow up appointment on Friday of which I will still be required to go to work, clock out at 10, drive all the way to this clinic by 11, do what needs to be done there and then report back to work.

What a strange turn of events this has turned into and my leg still fucking hurts while that rushing doctor told me to walk on it and stand on it to force the muscles to keep working. I need those painkillers man.

Need money tho.

Not clicking I'm not clicking it

Its Memorial Day Monday. Huge local travel holiday. They lower the price like that to make people think they are getting a deal. The gas station easily makes more due to having more customers to off set the 30 cent price cut.

In theory anyway.